Thrombogenicity of various endovascular stent types: An in vitro evaluation
Thrombogenicity of various endovascular stent types: An in vitro evaluation
复制标题
DOI：
10.1016/s1051-0443(07)61868-5
复制
发表时间：
2002-10-01
影响因子：
2.9
通讯作者：
Duda, SH
中科院分区：
文献类型：
--
作者：
Tepe, G;Wendel, HP;Duda, SH
目的：在标准化的新鲜全血体外模型中评价不同外周支架的血栓形成能力。材料和方法：将不同类型的支架(n=77，每种支架11种，n=7)植入聚氯乙烯管环，并填充供体血液样本。在血液循环120分钟后，检测凝血酶抗凝血酶III复合体(TAT)、β-血栓球蛋白(β-TG)和血小板计数。结果：2小时后，差异有统计学意义。所研究支架的TAT值(+/-SD)分别为31mug/mL+/-20(对照组)，328mug/mL+/-206(Saxx支架，外周介质为CrNi31 L)，651mug/mL+/-760(Palmaz Corinthian支架，316 L不锈钢，电抛光)，1609mug/mL+/-1264(Palmaz Corinthian支架，316 L不锈钢，非电抛光)，810mug/mL+/-578(Palmaz Schatz长介质支架)，569mug/mL+/-347(Smart Nitinol支架)，Megalink外周支架1,037个，+/-577个(Megalink外周支架)，543个(外周支架，电抛光)，1,674个(外周支架，非电抛光)，1,674个(外周支架，未电抛光)，3,128个(SelfX镍钛合金支架，抛光)，3,128个(SelfX镍钛合金支架，抛光)，5,897个(SelfX镍钛合金支架，未抛光)，和1,458个Mug/mL+/-887(桥式支架)。血小板计数(x1,000/MUL+/-SD)分别为218+/-35(对照组)，188+/-22(Saxx支架)，187+/-20(Palmaz Corinthian支架，电抛光)，135+/-37(Palmaz Corinthian支架，未电抛光)，170+/-24(Palmaz-Schatz支架)，180+/-36(Smart Nitinol支架)，159+/-26(Megalink外周支架)，173+/-17(外周支架，电抛光)，133+/-51(外周支架，非电抛光)，123+/-37(SelfX Nitinol，支架，非电抛光)抛光)，52+/-27(SelfX镍钛合金支架，未抛光)，130+/-31(桥式支架)。结论：这项标准化研究显示支架植入后广泛的血小板活化。电抛光明显降低了支架的血栓形成能力。
PURPOSE: The aim of this study was to evaluate the thrombogenicity of different peripheral stent types in a standardized in vitro model with fresh human whole blood.MATERIALS AND METHODS: Different stents (N = 77; n = 7 of each of 11 types) were implanted in polyvinyl chloride tubing loops and filled with donor blood samples. After 120 minutes of blood circulation, the thrombinantithrombin III complex (TAT) levels, beta-thromboglobulin (beta-TG) levels, and platelet counts were assessed.RESULTS: After 2 hours, significant differences were seen. TAT values ( +/- SD) with the investigated stents were 31 mug/mL +/- 20 (control, no stent), 328 mug/mL +/- 206 (Saxx stent, peripheral medium CrNi31 L), 651 mug/mL +/- 760 (Palmaz Corinthian Stent, 316 L stainless steel, electropolished), 1,609 mug/mL +/- 1,264 (Palmaz Corinthian Stent, 316 L stainless steel, not electropolished), 810 mug/mL +/- 578 (Palmaz Schatz long medium stent), 569 mug/mL +/- 347 (Smart Nitinol stent), 1,037 mug/mL +/- 577 (Megalink peripheral stent), 543 mug/mL +/- 487 (peripheral stent, electropolished), 1,674 mug/mL +/- 2,057 (peripheral stent, not electropolished), 3,128 mug/mL +/- 1,812 (SelfX Nitinol stent, polished), 5,897 mug/mL +/- 2,380 (SelfX Nitinol stent, unpolished), and 1,458 mug/mL +/- 887 (bridge stent). The platelet count (x1,000/muL +/- SD) was 218 +/- 35 (control, no stent), 188 +/- 22 (Saxx stent), 187 +/- 20 (Palmaz Corinthian stent, electropolished), 135 +/- 37 (Palmaz Corinthian stent, not electropolished), 170 +/- 24 (Palmaz Schatz stent), 180 +/- 36 (Smart Nitinol stent), 159 +/- 26 (Megalink peripheral stent), 173 +/- 17 (peripheral stent, electropolished), 133 +/- 51 (peripheral stent, not electropolished), 123 +/- 37 (SelfX Nitinol stent, polished), 52 +/- 27 (SelfX Nitinol stent, unpolished), and 130 +/- 31 (bridge stent).CONCLUSION: This standardized study showed a wide range of platelet activation after stent implantation. Electropolishing clearly reduced the thrombogenicity of the stents.